var data={"title":"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Frontotemporal dementia: Epidemiology, pathology, and pathogenesis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Suzee E Lee, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Bruce L Miller, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Steven T DeKosky, MD, FAAN, FACP, FANA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Janet L Wilterdink, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 20, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H10210219\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Frontotemporal dementia (FTD) is a clinically and neuropathologically heterogeneous disorder characterized by disturbances in behavior, personality and language accompanied by focal degeneration of the frontal <span class=\"nowrap\">and/or</span> temporal lobes. FTD serves as an umbrella term for several clinical syndromes, including behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent variant primary progressive aphasia (nfvPPA). </p><p>The term frontotemporal lobar degeneration (FTLD) is used commonly to denote the pathologic diagnoses associated with the clinical FTD spectrum. FTLD can be subdivided according to the nature of the characteristic cytoplasmic or nuclear protein inclusions that are observed histopathologically. In general, there is inconsistent correlation between clinical FTD syndromes and the underlying pathologic subtypes, which poses a challenge to the development and testing of therapies designed to target specific protein dysfunction in neurodegeneration. There is also increasing recognition of significant pathologic and genetic overlap between motor neuron disease and FTLD, as well as other neurodegenerative disorders. </p><p>This topic will review the epidemiology, pathogenesis and pathology of FTLD. The clinical manifestations, diagnosis and treatment of FTD are discussed separately. (See <a href=\"topic.htm?path=frontotemporal-dementia-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Frontotemporal dementia: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=frontotemporal-dementia-treatment\" class=\"medical medical_review\">&quot;Frontotemporal dementia: Treatment&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H10331468\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Frontotemporal dementia (FTD) is one of the more common causes of early-onset (midlife) dementia, occurring at similar frequency to Alzheimer disease (AD) in patients younger than 65 years. In a population-based study of early-onset dementia in Cambridgeshire, England, the incidence of FTD was estimated to be 3.5 cases per 100,000 person-years in adults aged 45 to 64 years, while the incidence of AD in the same age range was 4.2 per 100,000 person-years [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/1\" class=\"abstract_t\">1</a>]. Another study found an estimated prevalence of 15 cases per 100,000 for both FTD and AD in the 45 to 64 year age range [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/2\" class=\"abstract_t\">2</a>]. Since many FTD patients present with behavioral changes, it has been suggested that estimates of incidence and prevalence are conservative, since a subset of patients is likely to be referred to psychiatric services [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/2\" class=\"abstract_t\">2</a>].</p><p>The mean age of onset of FTD is about 58 years [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/3-8\" class=\"abstract_t\">3-8</a>]. The reported age of onset has ranged from 20 to 80 years, although onset before 40 or after 75 years of age is unusual.</p><p>In most case series, the proportion of men and women are roughly equal, but some have reported a male preponderance [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/2-5,8,9\" class=\"abstract_t\">2-5,8,9</a>].</p><p class=\"headingAnchor\" id=\"H10331476\"><span class=\"h1\">GENETIC FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Frontotemporal dementia (FTD) is highly heritable. A history of dementia or psychiatric conditions is present in 40 percent of patients, but without a clear inheritance pattern. An autosomal dominant pattern of inheritance is observed in approximately 10 to 25 percent of patients [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/4,5,7,8,10,11\" class=\"abstract_t\">4,5,7,8,10,11</a>]. </p><p>Patients with behavioral variant FTD (bvFTD), particularly when associated with motor neuron disease, are most likely to have an inherited condition; in one series, more than half of such patients demonstrated a family history consistent with autosomal dominant inheritance [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/11\" class=\"abstract_t\">11</a>].</p><p>Several genetic mutations have been identified that cause FTD or related disorders. Mutations in the <em>C9ORF72, MAPT, </em>and <em>GRN </em>genes together explain approximately 15 percent of familial FTD cohorts; mutations in other genes, including <em>VCP</em>, <em>CHMP2B,</em> and <em>TBK1,</em> are less common [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/12\" class=\"abstract_t\">12</a>]. The co-occurrence of two evidently pathogenic mutations in the same patient (eg, <em>C9ORF72 </em>expansion plus a mutation in either <em>GRN</em> or <em>MAPT</em>) has also been described [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/13\" class=\"abstract_t\">13</a>]. </p><p class=\"headingAnchor\" id=\"H4088549\"><span class=\"h2\">C9ORF72 gene</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A noncoding hexanucleotide repeat on chromosome 9, within the <em>C9ORF72</em> gene, is the most common genetic cause of familial FTD and familial amyotrophic lateral sclerosis (ALS). This mutation represents approximately 12 and 25 percent of familial cases, respectively [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/14,15\" class=\"abstract_t\">14,15</a>]. It has also been identified as a cause of some cases of sporadic ALS and FTD.</p><p>Possible pathophysiological mechanisms include haploinsufficiency of C9ORF72 protein, the development of repeat RNA foci, and abnormal dipeptide repeat proteins translated from the repeat mRNA [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/16\" class=\"abstract_t\">16</a>]. Also, defects in nucleocytoplasmic transport through the nuclear pore may contribute to disease [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/17-20\" class=\"abstract_t\">17-20</a>]. Some data suggest that tissue-specific expansion repeat length correlates with survival [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/21\" class=\"abstract_t\">21</a>]. <em>C9ORF72</em> expansions result in <span class=\"nowrap\">FTLD-ALS/DPR</span> pathology. (See <a href=\"#H3812377\" class=\"local\">'FTLD-ALS/DPR'</a> below.)</p><p>The predominant clinical presentation of <em>C9ORF72</em> carriers is bvFTD with or without motor neuron disease (FTD-MND), although cases of svPPA and nonfluent variant primary progressive aphasia (nfvPPA) have been described [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/22-24\" class=\"abstract_t\">22-24</a>]. In ALS, <em>C9ORF72</em> is associated with earlier disease onset, bulbar disease, higher frequency of comorbid FTD, and shorter age-matched median survival. (See <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis#H1808661\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;, section on 'C9ORF72 gene'</a>.)</p><p class=\"headingAnchor\" id=\"H25814656\"><span class=\"h2\">MAPT gene</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Over 40 different mutations in the microtubule associated protein tau (<em>MAPT)</em> gene on chromosome 17 have been reported in association with the clinical syndrome of FTD, parkinsonism and amyotrophy, also referred to as FTDP-17 [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/25\" class=\"abstract_t\">25</a>]. The mechanisms by which <em>MAPT</em> gene mutations result in FTD are not well understood; most mutations likely increase the tendency of tau to form neurotoxic aggregates as well as alter the ratio of the 3-repeat (3R) and 4R isoforms of tau. FTLD due to <em>MAPT</em> mutations is invariably of the FTLD-tau pathologic subtype, but the clinical phenotype is less predictable.</p><p>Carriers of <em>MAPT</em> mutations typically develop symptoms earlier than other genetic mutation-caused FTD cases, with symptoms typically beginning between the ages of 40 and 60 years [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/26\" class=\"abstract_t\">26</a>]. Clinical syndromes associated with <em>MAPT </em>mutations are heterogeneous and include behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). (See <a href=\"#H10210255\" class=\"local\">'FTLD-tau'</a> below and <a href=\"#H15049871\" class=\"local\">'Clinicopathologic correlations'</a> below.) </p><p class=\"headingAnchor\" id=\"H38116015\"><span class=\"h2\">GRN gene</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The gene encoding progranulin (<em>GRN</em>) also lies on chromosome 17. The function of progranulin is complex; it has been identified as a multifunctional growth factor in development, wound repair, and neuroinflammation, but its role in neurodegeneration is unknown [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/27-30\" class=\"abstract_t\">27-30</a>]. Nearly 70 mutations in <em>GRN</em> have been identified in association with FTLD, and all known mutations result in a truncated progranulin mRNA that undergoes nonsense-mediated decay via the nonsense-mediated surveillance system. This results in a haploinsufficiency of functional progranulin protein [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/31,32\" class=\"abstract_t\">31,32</a>]. Progranulin haploinsufficiency results in FTLD-TDP pathology; the mechanism by which this occurs remains unclear.</p><p>Mutation carriers exhibit principally bvFTD, nfvPPA or CBS. Age of onset ranges widely (35 to 87 years), but on average, disease onset occurs later than in <em>MAPT</em> carriers [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/27,33,34\" class=\"abstract_t\">27,33,34</a>]. In some patients with progranulin-associated FTD, magnetic resonance imaging (MRI) demonstrates extensive white matter lesions, in addition to the more typical pattern of focal frontal, temporal and parietal lobe atrophy [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/35\" class=\"abstract_t\">35</a>]. (See <a href=\"#H10210271\" class=\"local\">'FTLD-TDP'</a> below and <a href=\"#H15049871\" class=\"local\">'Clinicopathologic correlations'</a> below.) </p><p class=\"headingAnchor\" id=\"H38116064\"><span class=\"h2\">Other genes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Less common genetic causes of FTD include mutations in <em>VCP</em>, <em>CHMP2B</em>, <em>TBK1</em>, and <em>TARDBP, </em>the gene that encodes TDP-43. <em>VCP</em> is associated with bvFTD, inclusion body myositis, Paget&rsquo;s bone disease, and familial ALS [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/36-38\" class=\"abstract_t\">36-38</a>]. Mutations in <em>TARDBP</em> and <em>FUS</em> are linked to familial ALS but are rarely associated with FTD clinical presentations. (See <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis#H246948\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;, section on 'ALS14 (VCP gene)'</a> and <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis#H10\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;, section on 'ALS10 (TARDBP gene)'</a> and <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis#H6\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;, section on 'ALS6 (FUS gene)'</a>.)</p><p class=\"headingAnchor\" id=\"H10210231\"><span class=\"h1\">SHARED PATHOLOGIC FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The gross pathology of all frontotemporal lobar degeneration (FTLD) subtypes demonstrates damage in the frontal <span class=\"nowrap\">and/or</span> temporal lobes. Cortical <span class=\"nowrap\">and/or</span> basal ganglia atrophy may manifest symmetrically or asymmetrically; substantia nigra depigmentation occurs in a subset of cases. While the FTD clinical syndrome generally predicts damage to neuroanatomical structures, atrophy patterns are only loosely associated with underlying neuropathology. The one exception to this rule is semantic variant primary progressive aphasia (svPPA), which predominately affects the anterior temporal lobes.</p><p>Microscopically, most FTLD cases demonstrate microvacuolation and neuronal loss, accompanied by swollen neurons, loss of myelin, and astrocytic gliosis. In addition, abnormal protein inclusions are seen in the cytoplasm <span class=\"nowrap\">and/or</span> nuclei of neuronal <span class=\"nowrap\">and/or</span> glial cells. The constituents of these abnormal protein inclusions are now known in most cases and are used to classify FTLD pathology into distinct subtypes. The location and composition of the abnormal inclusions do not correlate well with clinical FTD subtypes. &#160; (See <a href=\"#H12834144\" class=\"local\">'Pathologic subtypes'</a> below and <a href=\"#H15049871\" class=\"local\">'Clinicopathologic correlations'</a> below.)</p><p class=\"headingAnchor\" id=\"H12834144\"><span class=\"h1\">PATHOLOGIC SUBTYPES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Frontotemporal lobar degeneration (FTLD) pathology is subdivided according to the composition of the abnormal inclusions. In approximately half of cases, the inclusions are made up of hyperphosphorylated tau protein; these cases are referred to as FTLD-tau. In the remaining tau-negative cases, previously referred to as dementia lacking distinctive histopathology (DLDH) [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/39\" class=\"abstract_t\">39</a>] and later as FTLD-ubiquitin (FTLD-U), the ubiquitinated protein has been identified in most cases as either 43 kD transactive response (TAR) DNA binding protein (TDP-43) or fused in sarcoma (FUS) protein [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/40\" class=\"abstract_t\">40</a>]. In cases with <em>C9ORF72</em> repeat expansions, the tau-negative inclusions contain TDP-negative dipeptide-repeat (DPR) proteins, and the pathologic subgroup is referred to as <span class=\"nowrap\">FTLD-ALS/DPR</span> [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/41\" class=\"abstract_t\">41</a>].</p><p>FTLD-tau and FTLD-TDP pathologies account for the majority of FTLD cases and occur with similar frequency [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/42\" class=\"abstract_t\">42</a>]. FTLD-FUS is less common, accounting for approximately 10 to 20 percent of FTLD-U cases and 5 to 10 percent of all FTLD cases [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/12\" class=\"abstract_t\">12</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H10210255\"><span class=\"h2\">FTLD-tau</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the earliest reported FTLD pathology, distinctive round, sliver-staining inclusions called Pick bodies were described, and the clinical syndrome was called Pick disease [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/43,44\" class=\"abstract_t\">43,44</a>]. Pick bodies were eventually determined to contain hyperphosphorylated tau protein inclusions [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/45\" class=\"abstract_t\">45</a>]. In recent years, &ldquo;Pick disease&rdquo; has evolved to denote one of the FTLD-tau subtypes, and it is no longer used to denote a specific clinical syndrome (since it is now recognized that FTLD-tau pathology can be seen in a range of clinical subtypes). (See <a href=\"#H15049871\" class=\"local\">'Clinicopathologic correlations'</a> below.)</p><p>Tau protein, encoded by the microtubule associated protein tau (<em>MAPT)</em> gene on chromosome 17, stabilizes microtubules, promotes microtubule assembly, and regulates axonal transport [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/46-48\" class=\"abstract_t\">46-48</a>]. Tau protein is alternatively spliced into six isoforms, among which are a three amino acid sequence repeat isoform (3R) and a four repeat isoform (4R). In normal cells, 3R and 4R tau occur in equal proportions; in FTLD-tau pathology, the ratio of 3R and 4R varies amongst pathologic subtypes.</p><p>In the subset of FTLD-tau pathology known as Pick disease, Pick bodies develop in the granule cells of the dentate gyrus, the pyramidal neurons in the CA1 region of the hippocampus, and the pyramidal neurons in the frontal and temporal lobes. Pick bodies are globose, tau-positive neuronal cytoplasmic inclusions composed primarily of 3R tau and occur in association with achromatic ballooned neurons, or Pick cells [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/49\" class=\"abstract_t\">49</a>]. Tau deposition in Pick disease progresses sequentially, beginning in the frontotemporal <span class=\"nowrap\">limbic/paralimbic</span> and neocortical regions, then involving subcortical structures (eg, basal ganglia, locus ceruleus, raphe nuclei), primary motor cortex and precerebellar nuclei, and finally visual cortex [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/50\" class=\"abstract_t\">50</a>]. </p><p>Aside from Pick disease, rarer FTLD-tau pathologies include pathology of <em>MAPT</em> mutation carriers, argyrophilic grain disease, and multiple system tauopathy.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>FTLD with a <em>MAPT</em> mutation, also known as FTD with parkinsonism linked to chromosome 17 (FTDP-17), exhibits a mixture of 3R and 4R tau pathologies. (See <a href=\"#H10331476\" class=\"local\">'Genetic factors'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Argyrophilic grain disease pathology consists of 4R tau-positive astrocytes, coiled bodies, and ovoid bodies that are present in medial temporal lobes and limbic regions [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/51\" class=\"abstract_t\">51</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple system tauopathy is a rare, 4R tau pathology characterized by globular neuronal and glial tau-positive inclusions in gray and white matter [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/52\" class=\"abstract_t\">52</a>]. </p><p/><p>FTLD-tau also encompasses corticobasal degeneration and progressive supranuclear palsy, which are discussed separately. (See <a href=\"topic.htm?path=corticobasal-degeneration#H168533548\" class=\"medical medical_review\">&quot;Corticobasal degeneration&quot;, section on 'Pathology and pathophysiology'</a> and <a href=\"topic.htm?path=progressive-supranuclear-palsy-psp-clinical-features-and-diagnosis#H5944894\" class=\"medical medical_review\">&quot;Progressive supranuclear palsy (PSP): Clinical features and diagnosis&quot;, section on 'Pathology and pathophysiology'</a>.)</p><p class=\"headingAnchor\" id=\"H10210271\"><span class=\"h2\">FTLD-TDP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>TDP-43 protein is a ribonucleic acid (RNA) binding protein present in the nucleus of normal cells and involved in transcription regulation [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/53-56\" class=\"abstract_t\">53-56</a>]. In FTLD-TDP, abnormally phosphorylated and ubiquitinated TDP-43 appears in various abnormal morphologies, including neuronal cytoplasmic inclusions (NCIs), neuronal intranuclear inclusions, dystrophic neurites, and glial cytoplasmic inclusions [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/53,55-57\" class=\"abstract_t\">53,55-57</a>]. Based on the types of inclusions and their distribution throughout the brain, FTLD-TDP can be further subdivided into four types [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/58\" class=\"abstract_t\">58</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Type A, with many NCIs and many dystrophic neurites</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Type B, with moderate NCIs and few dystrophic neurites</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Type C, with few NCIs and many long dystrophic neurites</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Type D, with few NCIs, many short dystrophic neurites and many lentiform neuronal intranuclear inclusions</p><p/><p>Type A is the most common subtype, accounting for approximately 40 to 50 percent of FTLD-TDP cases, followed by type B (approximately 30 percent), type C (up to 25 percent), and type D, which is rare [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/55,59\" class=\"abstract_t\">55,59</a>]. The mechanisms through which TDP-43 protein abnormalities lead to neurodegeneration are a focus of intense research, but are not yet understood.</p><p>Several autosomal dominant mutations known to cause FTD &quot;spectrum disorders&quot; result in FTLD-TDP pathology:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>FTD caused by mutations in the <em>GRN</em> gene [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/31,60\" class=\"abstract_t\">31,60</a>] is associated with FTLD-TDP type A pathology. (See <a href=\"#H10331476\" class=\"local\">'Genetic factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inclusion body myositis with Paget&rsquo;s disease of bone and FTD, caused by valosin-containing protein (<em>VCP</em>) gene mutations [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/61\" class=\"abstract_t\">61</a>], results in type D pathology. (See <a href=\"#H10331476\" class=\"local\">'Genetic factors'</a> above.)</p><p/><p>TDP-43 inclusions are also seen in most cases of amyotrophic lateral sclerosis (ALS), even in patients who do not have clinical FTD symptomatology [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/62,63\" class=\"abstract_t\">62,63</a>]. Based on the significant clinical and pathological overlap among FTLD-TDP with or without motor neuron disease and TDP-positive ALS with or without dementia, it has been suggested that these TDP-43 proteinopathies exist along one continuous clinicopathological spectrum of multi-system neurodegenerative diseases [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/64\" class=\"abstract_t\">64</a>]. (See <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis#H8\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of amyotrophic lateral sclerosis&quot;, section on 'Pathology'</a>.)</p><p class=\"headingAnchor\" id=\"H3812377\"><span class=\"h2\">FTLD-ALS/DPR</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The neuropathology of <em>C9ORF72</em> hexanucleotide repeat carriers is characterized by TDP-negative dipeptide-repeat proteins that aggregate in the cerebellum and hippocampus, in addition to FTLD-TDP type B pathology. Some aggregates occur adjacent to TDP type A or B inclusions, while in other inclusions the dipeptide repeats represent the sole constituent of the aggregate [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/65\" class=\"abstract_t\">65</a>].</p><p class=\"headingAnchor\" id=\"H10210293\"><span class=\"h2\">FTLD-FUS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most cases of TDP-negative FTLD-U have inclusions staining positively for fused in sarcoma (FUS) protein [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/40\" class=\"abstract_t\">40</a>]. FUS is a multifunctional DNA- and RNA-binding protein that shares functional homology with TDP-43. Mutations in the gene coding for FUS protein were originally identified as a cause of familial ALS. (See <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis#H6\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;, section on 'ALS6 (FUS gene)'</a>.) </p><p>The FTLD-FUS group also includes basophilic inclusions body disease (BIBD) and neuronal intermediate filament inclusion disease (NIFID), since the inclusions in these conditions are now known to be FUS immunoreactive [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/66,67\" class=\"abstract_t\">66,67</a>]. </p><p class=\"headingAnchor\" id=\"H15049871\"><span class=\"h1\">CLINICOPATHOLOGIC CORRELATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, clinical frontotemporal dementia (FTD) syndromes correlate relatively well with the site of neurodegeneration and pattern of brain atrophy, but not with the underlying pathologic subtype [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/68\" class=\"abstract_t\">68</a>]. </p><p>FTLD-tau pathology is most commonly associated with behavioral variant FTD (bvFTD) and less commonly with nonfluent variant primary progressive aphasia (nfvPPA). (See <a href=\"topic.htm?path=frontotemporal-dementia-clinical-features-and-diagnosis#H533509426\" class=\"medical medical_review\">&quot;Frontotemporal dementia: Clinical features and diagnosis&quot;, section on 'Behavioral variant FTD'</a>.) </p><p>Within FTLD-TDP, common clinical syndromes for type A include bvFTD and nfvPPA [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/58,69\" class=\"abstract_t\">58,69</a>]. Type B mostly commonly appears as bvFTD with or without motor neuron disease. Type C usually presents as semantic variant PPA (svPPA) or bvFTD [<a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/69\" class=\"abstract_t\">69</a>]. (See <a href=\"topic.htm?path=frontotemporal-dementia-clinical-features-and-diagnosis#H533510559\" class=\"medical medical_review\">&quot;Frontotemporal dementia: Clinical features and diagnosis&quot;, section on 'Primary progressive aphasia'</a>.)</p><p>FTLD-FUS is an exception: it appears to result reliably in the bvFTD phenotype, usually in association with ALS.</p><p class=\"headingAnchor\" id=\"H12834411\"><span class=\"h1\">SUMMARY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Frontotemporal dementia (FTD) is a clinically and neuropathologically heterogeneous disorder characterized by disturbances in behavior, personality and language accompanied by focal degeneration of the frontal <span class=\"nowrap\">and/or</span> temporal lobes. The term frontotemporal lobar degeneration (FTLD) is used to denote the pathologic diagnoses associated with the clinical FTD spectrum.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>FTD is a common cause of early-onset (midlife) dementia, occurring at similar frequency to Alzheimer disease in patients younger than 65 years. The mean age of onset is 58 years, and there may be a slight male predominance. (See <a href=\"#H10331468\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The gross pathology of FTLD includes symmetrical or asymmetrical atrophy in the frontal <span class=\"nowrap\">and/or</span> temporal lobes. Characteristic microscopic findings include microvacuolation and neuronal loss, accompanied by swollen neurons, loss of myelin, and astrocytic gliosis. In addition, abnormal protein inclusions are seen in the cytoplasm <span class=\"nowrap\">and/or</span> nuclei of neuronal <span class=\"nowrap\">and/or</span> glial cells. (See <a href=\"#H10331476\" class=\"local\">'Genetic factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>On gross pathology, FTLD demonstrates symmetrical or asymmetrical atrophy in the frontal <span class=\"nowrap\">and/or</span> temporal lobes. Characteristic microscopic findings include microvacuolation and neuronal loss, accompanied by swollen neurons, loss of myelin, and astrocytic gliosis. In addition, abnormal protein inclusions are seen in the cytoplasm <span class=\"nowrap\">and/or</span> nuclei of neuronal <span class=\"nowrap\">and/or</span> glial cells. (See <a href=\"#H10210231\" class=\"local\">'Shared pathologic features'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>FTLD can be subdivided according to the nature of the inclusions that are observed histopathologically. Most cases reveal inclusions comprised of hyperphosphorylated tau protein or the 43 kD transactive response (TAR) DNA binding protein (TDP-43) protein. FTLD due to fused in sarcoma (FUS) protein is less common. (See <a href=\"#H12834144\" class=\"local\">'Pathologic subtypes'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>FTLD-tau comprises several different pathologic subtypes. In Pick disease, distinctive round, sliver-staining inclusions made up of hyperphosphorylated tau are seen in the dentate gyrus and the pyramidal neurons of the CA1 region of the hippocampus, temporal and frontal lobes. In addition to Pick disease, FTLD-tau also includes corticobasal degeneration, progressive supranuclear palsy, the pathology of <em>MAPT</em> mutation carriers, argyrophilic grain disease, and multiple system tauopathy. (See <a href=\"#H10210255\" class=\"local\">'FTLD-tau'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In FTLD-TDP, abnormally phosphorylated and ubiquitinated TDP-43 appears as various morphologies, including neuronal cytoplasmic inclusions (NCIs), neuronal intranuclear inclusions, dystrophic neurites, and glial cytoplasmic inclusions. FTLD-TDP pathology is seen in association with several heritable forms of FTD, including those caused by mutations in granulin (<em>GRN)</em> and valosin-containing protein (<em>VAP)</em>. (See <a href=\"#H10210271\" class=\"local\">'FTLD-TDP'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>FTD clinical syndromes correlate relatively well with the site of neurodegeneration and pattern of brain atrophy, but not with the underlying pathologic subtype. (See <a href=\"#H15049871\" class=\"local\">'Clinicopathologic correlations'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/1\" class=\"nounderline abstract_t\">Mercy L, Hodges JR, Dawson K, et al. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology 2008; 71:1496.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/2\" class=\"nounderline abstract_t\">Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002; 58:1615.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/3\" class=\"nounderline abstract_t\">Johnson JK, Diehl J, Mendez MF, et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol 2005; 62:925.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/4\" class=\"nounderline abstract_t\">Rosso SM, Donker Kaat L, Baks T, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 2003; 126:2016.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/5\" class=\"nounderline abstract_t\">Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004; 56:399.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/6\" class=\"nounderline abstract_t\">Grossman M. Frontotemporal dementia: a review. J Int Neuropsychol Soc 2002; 8:566.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/7\" class=\"nounderline abstract_t\">Hodges JR, Davies R, Xuereb J, et al. Survival in frontotemporal dementia. Neurology 2003; 61:349.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/8\" class=\"nounderline abstract_t\">Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006; 59:156.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/9\" class=\"nounderline abstract_t\">Mesulam MM. Primary progressive aphasia. Ann Neurol 2001; 49:425.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/10\" class=\"nounderline abstract_t\">Le Ber I, Guedj E, Gabelle A, et al. Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain 2006; 129:3051.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/11\" class=\"nounderline abstract_t\">Goldman JS, Farmer JM, Wood EM, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 2005; 65:1817.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/12\" class=\"nounderline abstract_t\">Sieben A, Van Langenhove T, Engelborghs S, et al. The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol 2012; 124:353.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/13\" class=\"nounderline abstract_t\">van Blitterswijk M, Baker MC, DeJesus-Hernandez M, et al. C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology 2013; 81:1332.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/14\" class=\"nounderline abstract_t\">Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72:257.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/15\" class=\"nounderline abstract_t\">DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72:245.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/16\" class=\"nounderline abstract_t\">Gendron TF, Belzil VV, Zhang YJ, Petrucelli L. Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol 2014; 127:359.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/17\" class=\"nounderline abstract_t\">Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 2014; 507:195.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/18\" class=\"nounderline abstract_t\">Zhang K, Donnelly CJ, Haeusler AR, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 2015; 525:56.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/19\" class=\"nounderline abstract_t\">Freibaum BD, Lu Y, Lopez-Gonzalez R, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 2015; 525:129.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/20\" class=\"nounderline abstract_t\">Jovi&#269;i&#263; A, Mertens J, Boeynaems S, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci 2015; 18:1226.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/21\" class=\"nounderline abstract_t\">van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 2013; 12:978.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/22\" class=\"nounderline abstract_t\">Sha SJ, Takada LT, Rankin KP, et al. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology 2012; 79:1002.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/23\" class=\"nounderline abstract_t\">Sim&oacute;n-S&aacute;nchez J, Dopper EG, Cohn-Hokke PE, et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain 2012; 135:723.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/24\" class=\"nounderline abstract_t\">Rohrer JD, Isaacs AM, Mizielinska S, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol 2015; 14:291.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/25\" class=\"nounderline abstract_t\">Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393:702.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/26\" class=\"nounderline abstract_t\">Seelaar H, Kamphorst W, Rosso SM, et al. Distinct genetic forms of frontotemporal dementia. Neurology 2008; 71:1220.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/27\" class=\"nounderline abstract_t\">Bruni AC, Momeni P, Bernardi L, et al. Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation. Neurology 2007; 69:140.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/28\" class=\"nounderline abstract_t\">He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berl) 2003; 81:600.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/29\" class=\"nounderline abstract_t\">Zhu J, Nathan C, Jin W, et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002; 111:867.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/30\" class=\"nounderline abstract_t\">Chitramuthu BP, Bennett HPJ, Bateman A. Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. Brain 2017; 140:3081.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/31\" class=\"nounderline abstract_t\">Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442:916.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/32\" class=\"nounderline abstract_t\">Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006; 442:920.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/33\" class=\"nounderline abstract_t\">Pickering-Brown SM, Rollinson S, Du Plessis D, et al. Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain 2008; 131:721.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/34\" class=\"nounderline abstract_t\">Rizzu P, van Mil SE, Anar B, et al. CHMP2B mutations are not a cause of dementia in Dutch patients with familial and sporadic frontotemporal dementia. Am J Med Genet B Neuropsychiatr Genet 2006; 141B:944.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/35\" class=\"nounderline abstract_t\">Caroppo P, Le Ber I, Camuzat A, et al. Extensive white matter involvement in patients with frontotemporal lobar degeneration: think progranulin. JAMA Neurol 2014; 71:1562.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/36\" class=\"nounderline abstract_t\">Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68:857.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/37\" class=\"nounderline abstract_t\">Gijselinck I, Van Mossevelde S, van der Zee J, et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology 2015; 85:2116.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/38\" class=\"nounderline abstract_t\">Van Mossevelde S, van der Zee J, Gijselinck I, et al. Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Brain 2016; 139:452.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/39\" class=\"nounderline abstract_t\">Knopman DS, Mastri AR, Frey WH 2nd, et al. Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology 1990; 40:251.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/40\" class=\"nounderline abstract_t\">Urwin H, Josephs KA, Rohrer JD, et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol 2010; 120:33.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/41\" class=\"nounderline abstract_t\">Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2012; 72:257.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/42\" class=\"nounderline abstract_t\">Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol 2007; 114:31.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/43\" class=\"nounderline abstract_t\">Pick A. Ueber die Beiehungen der senilen Hirnatrophie zur Aphasie. Prager Medicinische Wochenschrift 1892; 17:165.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/44\" class=\"nounderline abstract_t\">Alzheimer A. &Uuml;ber eigenartige Krankheitsf&auml;lle des sp&auml;teren Alters. Z Gesamte Neurol Psychiatr 1911; 4:356.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/45\" class=\"nounderline abstract_t\">Arima K, Nakamura M, Sunohara N, et al. Ultrastructural characterization of the tau-immunoreactive tubules in the oligodendroglial perikarya and their inner loop processes in progressive supranuclear palsy. Acta Neuropathol 1997; 93:558.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/46\" class=\"nounderline abstract_t\">Ebneth A, Godemann R, Stamer K, et al. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 1998; 143:777.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/47\" class=\"nounderline abstract_t\">Sato-Harada R, Okabe S, Umeyama T, et al. Microtubule-associated proteins regulate microtubule function as the track for intracellular membrane organelle transports. Cell Struct Funct 1996; 21:283.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/48\" class=\"nounderline abstract_t\">Hirokawa N, Funakoshi T, Sato-Harada R, Kanai Y. Selective stabilization of tau in axons and microtubule-associated protein 2C in cell bodies and dendrites contributes to polarized localization of cytoskeletal proteins in mature neurons. J Cell Biol 1996; 132:667.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/49\" class=\"nounderline abstract_t\">Zhukareva V, Mann D, Pickering-Brown S, et al. Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol 2002; 51:730.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/50\" class=\"nounderline abstract_t\">Irwin DJ, Brettschneider J, McMillan CT, et al. Deep clinical and neuropathological phenotyping of Pick disease. Ann Neurol 2016; 79:272.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/51\" class=\"nounderline abstract_t\">Braak H, Braak E. Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol Appl Neurobiol 1989; 15.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/52\" class=\"nounderline abstract_t\">Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007; 114:5.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/53\" class=\"nounderline abstract_t\">Davidson Y, Kelley T, Mackenzie IR, et al. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 2007; 113:521.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/54\" class=\"nounderline abstract_t\">Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006; 351:602.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/55\" class=\"nounderline abstract_t\">Cairns NJ, Neumann M, Bigio EH, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 2007; 171:227.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/56\" class=\"nounderline abstract_t\">Neumann M, Mackenzie IR, Cairns NJ, et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 2007; 66:152.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/57\" class=\"nounderline abstract_t\">Sampathu DM, Neumann M, Kwong LK, et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 2006; 169:1343.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/58\" class=\"nounderline abstract_t\">Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122:111.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/59\" class=\"nounderline abstract_t\">Josephs KA, Hodges JR, Snowden JS, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 2011; 122:137.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/60\" class=\"nounderline abstract_t\">Cruts M, Rademakers R, Gijselinck I, et al. Genomic architecture of human 17q21 linked to frontotemporal dementia uncovers a highly homologous family of low-copy repeats in the tau region. Hum Mol Genet 2005; 14:1753.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/61\" class=\"nounderline abstract_t\">Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004; 36:377.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/62\" class=\"nounderline abstract_t\">Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314:130.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/63\" class=\"nounderline abstract_t\">Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61:427.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/64\" class=\"nounderline abstract_t\">Geser F, Lee VM, Trojanowski JQ. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology 2010; 30:103.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/65\" class=\"nounderline abstract_t\">Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS. Science 2013.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/66\" class=\"nounderline abstract_t\">Munoz DG, Neumann M, Kusaka H, et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol 2009; 118:617.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/67\" class=\"nounderline abstract_t\">Neumann M, Roeber S, Kretzschmar HA, et al. Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 2009; 118:605.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/68\" class=\"nounderline abstract_t\">Mesulam MM, Weintraub S, Rogalski EJ, et al. Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. Brain 2014; 137:1176.</a></li><li><a href=\"https://www.uptodate.com/contents/frontotemporal-dementia-epidemiology-pathology-and-pathogenesis/abstract/69\" class=\"nounderline abstract_t\">Spinelli EG, Mandelli ML, Miller ZA, et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol 2017; 81:430.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 14138 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H12834411\"><span>SUMMARY</span></a></li><li><a href=\"#H10210219\" id=\"outline-link-H10210219\">INTRODUCTION</a></li><li><a href=\"#H10331468\" id=\"outline-link-H10331468\">EPIDEMIOLOGY</a></li><li><a href=\"#H10331476\" id=\"outline-link-H10331476\">GENETIC FACTORS</a><ul><li><a href=\"#H4088549\" id=\"outline-link-H4088549\">C9ORF72 gene</a></li><li><a href=\"#H25814656\" id=\"outline-link-H25814656\">MAPT gene</a></li><li><a href=\"#H38116015\" id=\"outline-link-H38116015\">GRN gene</a></li><li><a href=\"#H38116064\" id=\"outline-link-H38116064\">Other genes</a></li></ul></li><li><a href=\"#H10210231\" id=\"outline-link-H10210231\">SHARED PATHOLOGIC FEATURES</a></li><li><a href=\"#H12834144\" id=\"outline-link-H12834144\">PATHOLOGIC SUBTYPES</a><ul><li><a href=\"#H10210255\" id=\"outline-link-H10210255\">FTLD-tau</a></li><li><a href=\"#H10210271\" id=\"outline-link-H10210271\">FTLD-TDP</a></li><li><a href=\"#H3812377\" id=\"outline-link-H3812377\">FTLD-ALS/DPR</a></li><li><a href=\"#H10210293\" id=\"outline-link-H10210293\">FTLD-FUS</a></li></ul></li><li><a href=\"#H15049871\" id=\"outline-link-H15049871\">CLINICOPATHOLOGIC CORRELATIONS</a></li><li><a href=\"#H12834411\" id=\"outline-link-H12834411\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=corticobasal-degeneration\" class=\"medical medical_review\">Corticobasal degeneration</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">Epidemiology and pathogenesis of amyotrophic lateral sclerosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">Familial amyotrophic lateral sclerosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=frontotemporal-dementia-clinical-features-and-diagnosis\" class=\"medical medical_review\">Frontotemporal dementia: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=frontotemporal-dementia-treatment\" class=\"medical medical_review\">Frontotemporal dementia: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=progressive-supranuclear-palsy-psp-clinical-features-and-diagnosis\" class=\"medical medical_review\">Progressive supranuclear palsy (PSP): Clinical features and diagnosis</a></li></ul></div></div>","javascript":null}